Preliminary studies suggested that octreotide may be therapeutic in bleeding angiodysplasia.
Dr Félix Junquera and colleagues from Spain investigated the efficacy of long-term octreotide therapy preventing rebleeding from gastrointestinal (GI) angiodysplasia.
The investigators evaluated a cohort of 32 patients diagnosed with bleeding from angiodysplasia.
The patients were treated with octreotide 50 µ 12 hours subcutaneously for a 1 to 2 year period.
|About 55% remained free of rebleeding at 1 year|
|American Journal of Gastroenteorlogy|
The investigators compared this cohort with an external control group.
The control group included 38 patients who had received placebo in a concurrent randomized clinical trial for the same period.
The investigative team found that 2 patients of the octreotide group were lost to follow-up.
Treatment failure occurred in 7 of 30 patients in the octreotide group and in 17 of 35 in the placebo group.
The actuarial probability of remaining free of rebleeding at 1 and 2 years of follow-up was 77% and 68%, respectively for the octreotide group.
The investigators noted that the probability of remaining free of rebleeding at 1 and 2 years of follow-up was 55% and 36%, respectively, for the placebo group.
Multivariate proportional hazards-regression analysis showed that octreotide therapy was a positive predictor of efficacy.
The team showed that previous bleeding episodes were a negative predictor of efficacy.
The investigators observed no significant differences between the groups according to number of bleeding episodes.
There were no differences between groups according to transfusion requirements.
However, the investigative team found that iron requirements were lower in the octreotide than in the placebo group.
The team noted that major adverse events and mortality were similar between the groups.
Dr Junquera's team concludes, “This study suggests that octreotide treatment may be beneficial in preventing rebleeding from gastrointestinal angiodysplasia.”